Fig. 1 · Structure

Documents & Downloads

Citalopram Hydrobromide

Cat. No. A10222 CAS 59729-32-7
Citalopram is a selective inhibitor of ST (5-hydroxytryptamine/serotonin transporter) and therefore is a potent and selective serotonin reuptake inhibitor.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Citalopram hydrobromide inhibits serotonin uptake in mouse synaptosomes. The SERT Met172 substitution reduced citalopram potency while preserving basal transport and paroxetine sensitivity, supporting a SERT-mediated uptake mechanism in this preparation. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Citalopram Hydrobromide Research Summary

This section summarizes 1 in vitro study and 2 in vivo studies of Citalopram Hydrobromide from 2 published references.

Citalopram Hydrobromide In Vitro Studies

SERT-dependent inhibition of serotonin uptake in mouse synaptosomes

Biochemical assay · Midbrain synaptosomes from 8–12-week-old male WT Ile172 and SERT Met172 mice on a congenic C57BL/6J background; both SERT alleles share the 129-derived E39R152 haplotype. [1]

Citalopram inhibited radiolabeled serotonin uptake with lower potency in Met172 than WT preparations. Basal expression and saturation uptake did not significantly differ; paroxetine inhibition was preserved.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Citalopram inhibition of [3H]5-HT uptakeKI WT: 2.07 ± 0.05 × 10^-8 M; Met172: 7.91 ± 0.05 × 10^-6 M; n=4 per genotype and condition[1]
Paroxetine inhibition and baseline controlsControl comparison Paroxetine KI: WT 2.00 ± 0.03 × 10^-9 M; Met172 1.80 ± 0.04 × 10^-9 M; n=4 per genotype and condition. SERT expression: P>0.05, n=5/genotype; saturation transport: P>0.05, n=6/genotype.[1]

Literature-Reported Treatment Conditions

Treatment concentration
Varying inhibitor concentrations; 20 nM [3H]5-HT
Exposure duration
10 min at 37 °C
Method
Competition uptake assay in isolated synaptosomes
Co-treatment
No combination treatment; paroxetine and fluoxetine were separate comparator inhibitors.
Reported limits
Exact inhibitor dilution series and assay vehicle not specified in the read methods; ± statistic for competition KI values is not defined in the caption.
Methods and source locations

Compound reported in the paper: Citalopram hydrobromide; Compound label in the paper: citalopram HBr

Evidence for the reported citalopram hydrobromide material; no Adooq lot validation, salt conversion or isolated-enantiomer equivalence.

Published PDF pp. 1734–1737: Drugs; Synaptosomal 5-HT Uptake; Results; Figure 1a–c and caption

Citalopram inhibition of [3H]5-HT uptake: Reported Figure 1c caption values; ± meaning not explicitly assigned there. These are inhibition constants, not treatment doses. — Published PDF pp. 1734–1737: Drugs; Synaptosomal 5-HT Uptake; Results; Figure 1a–c and caption

Paroxetine inhibition and baseline controls: Figure 1a–c; expression normalized to β-actin; saturation uptake uses whole-brain preparations and 1 μM paroxetine to define nonspecific uptake. — Published PDF pp. 1734–1737: Drugs; Synaptosomal 5-HT Uptake; Results; Figure 1a–c and caption

Citalopram Hydrobromide In Vivo Studies

Continuous citalopram hydrobromide exposure reduced a forebrain serotonin-synthesis index in male C57BL/6J mice at 2, 14 and 28 days. This was measured during acute decarboxylase inhibition. Without that challenge, total forebrain serotonin was not significantly changed at individual time points, limiting conclusions about depletion. [2]

Serotonin synthesis during continuous citalopram exposure

Animal study · Adult male C57BL/6J mice; forebrain biochemical measurements after continuous minipump treatment and acute decarboxylase inhibition. [2]

Under the NSD-1015 challenge, forebrain 5-HTP accumulation was lower after 2, 14 and 28 days of citalopram than after matched saline treatment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Forebrain 5-HTP accumulation, an index of serotonin synthesisDecrease relative to time-matched saline 2 days: 36%, p<0.001; 14 days: 24%, p<0.01; 28 days: 20%, p<0.05. CIT/SAL n: 6/6, 8/7, 7/10, respectively.[2]
Forebrain serotonin content after acute NSD-1015 challengeDecrease relative to time-matched saline 14 days: 18% decrease, p<0.01; 28 days: 20% decrease, p<0.01; 2 days: p>0.05. Same challenged cohorts as 5-HTP measurement.[2]

Conditions shared by the study groups

Route
Continuous implanted osmotic minipump; implantation site not reported
Frequency
Continuous
Treatment course
2, 14 or 28 days
Vehicle
0.9% NaCl
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Citalopram versus matched saline
Approximately 24 mg/kg/day (reported); pump filled with 10% citalopram hydrobromide
Time-matched saline-filled minipumps; both treatment groups received NSD-1015Under the NSD-1015 challenge, forebrain 5-HTP accumulation was lower after 2, 14 and 28 days of citalopram than after matched saline treatment.[2]
Citalopram versus matched saline
Model: Adult male C57BL/6J mice; forebrain biochemical measurements after continuous minipump treatment and acute decarboxylase inhibition.
Reported limits: Anatomical implantation site not reported; concentration percentage basis not further specified.
Methods and source locations

Compound reported in the paper: Citalopram hydrobromide; Compound label in the paper: CIT

Evidence for the reported citalopram hydrobromide material; no Adooq lot validation, salt conversion or isolated-enantiomer equivalence.

Results; Figure 1B and Figure 2B/captions; Materials and Methods: Animals & Surgery, Groups & Treatments, sample analysis and statistics

Forebrain 5-HTP accumulation, an index of serotonin synthesis: HPLC with electrochemical detection after decarboxylase blockade; two-way ANOVA and Bonferroni post-tests. Percentages are stated in Results, not read from bars. — Results; Figure 1B and Figure 2B/captions; Materials and Methods: Animals & Surgery, Groups & Treatments, sample analysis and statistics

Forebrain serotonin content after acute NSD-1015 challenge: HPLC with electrochemical detection; Figure 2B and Results; Bonferroni post-tests. — Results; Figure 1B and Figure 2B/captions; Materials and Methods: Animals & Surgery, Groups & Treatments, sample analysis and statistics

Citalopram versus matched saline · Results; Figure 1B and Figure 2B/captions; Materials and Methods: Animals & Surgery, Groups & Treatments, sample analysis and statistics

Forebrain serotonin content without synthesis blockade

Animal study · Adult male C57BL/6J mice; separate non-NSD-1015 cohorts after minipump treatment. [2]

Without NSD-1015, citalopram had a significant overall treatment effect on forebrain serotonin content, but no individual time-point comparison was significant.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Forebrain serotonin content without NSD-1015Statistical comparison Overall treatment effect: p=0.04 (ANOVA); all individual time points: p>0.05 (Bonferroni post-tests). CIT/SAL n: 8/8 at 2 days, 8/9 at 14 days, 7/7 at 28 days.[2]

Conditions shared by the study groups

Route
Continuous implanted osmotic minipump; implantation site not reported
Frequency
Continuous
Treatment course
2, 14 or 28 days
Vehicle
0.9% NaCl
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Citalopram versus matched saline
Approximately 24 mg/kg/day (reported); pump filled with 10% citalopram hydrobromide
Time-matched saline-filled minipumps; no NSD-1015 in either groupWithout NSD-1015, citalopram had a significant overall treatment effect on forebrain serotonin content, but no individual time-point comparison was significant.[2]
Citalopram versus matched saline
Model: Adult male C57BL/6J mice; separate non-NSD-1015 cohorts after minipump treatment.
Reported limits: Anatomical implantation site not reported; concentration percentage basis not further specified.
Methods and source locations

Compound reported in the paper: Citalopram hydrobromide; Compound label in the paper: CIT

Evidence for the reported citalopram hydrobromide material; no Adooq lot validation, salt conversion or isolated-enantiomer equivalence.

Results paragraphs on forebrain 5-HT content; Figure 2A/caption; Materials and Methods: non-NSD-1015 groups and HPLC-ED

Forebrain serotonin content without NSD-1015: HPLC with electrochemical detection; Figure 2A; groups without additional pre-sampling drug treatment. — Results paragraphs on forebrain 5-HT content; Figure 2A/caption; Materials and Methods: non-NSD-1015 groups and HPLC-ED

Citalopram versus matched saline · Results paragraphs on forebrain 5-HT content; Figure 2A/caption; Materials and Methods: non-NSD-1015 groups and HPLC-ED

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 59729-32-7
Formula C20H22BrFN2O
Molecular Weight 405.31
SMILES
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 80 mg/mL (197.38 mM)
Water Warmed: 80 mg/mL (197.38 mM)
Ethanol Warmed: 80 mg/mL (197.38 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Citalopram Hydrobromide Research References

  1. [1] Alex G Nackenoff, Alexandra B Moussa-Tooks, Austin M McMeekin, et al. Essential Contributions of Serotonin Transporter Inhibition to the Acute and Chronic Actions of Fluoxetine and Citalopram in the SERT Met172 Mouse Neuropsychopharmacology (2016). PMID: 26514584 DOI: 10.1038/npp.2015.335 Source material
  2. [2] Gerard Honig, Minke E. Jongsma, Marieke C. G. van der Hart, et al. Chronic Citalopram Administration Causes a Sustained Suppression of Serotonin Synthesis in the Mouse Forebrain PLoS ONE (2009). PMID: 19710918 DOI: 10.1371/journal.pone.0006797 Source material

Added to your cart

View Cart Checkout
Loading...